assessed the impact of IL-6 blockers on long-term immunity in COVID-19 patients and found significantly higher median serum anti-trimeric spike IgG levels (295 vs. 121 BAU/mL; P = 0.011) and neutralizing antibodies (74.7 vs. 41.0%IH; P = 0.012) within one year post-infection in patients receiving anti-IL-6 therapy. The gene discussed is IL6; the disease is COVID-19.